In part 7, we made the case that white glove patient support services are the operational backbone behind CGT patient engagement, and that standard hub models fall short of what CGT patients actually need. That operational backbone, however, is only as strong as the teams executing against it. Field, medical, and access professionals across the manufacturer’s organization must operate at a level of scientific and operational fluency that significantly exceeds what specialty pharma typically requires, and they must do so in tight coordination with one another. In this post, we look at what it takes to build that internal capability and why coordination failures inside the manufacturer often show up as trust failures outside it.

Higher Science Demands Higher Expertise

CGTs raise the bar for every externally facing manufacturer role. Each stakeholder that these teams engage with, including authorized treatment center (ATC) medical directors, apheresis staff (modality dependent), treating physicians, health-system pharmacists, payer medical directors, patient advocacy leaders, and others, not only expect, but require a level of scientific and operational fluency that typical biopharma training does not produce. A field team member who can recite mechanism-of-action slides but cannot discuss the practical implications of lymphodepletion timing, vector selection, or manufacturing turnaround will not establish credibility. Without credibility, the downstream work in referral, access, and patient support gets slower and harder at every step.

The practical implications for training and role design are substantial:

  • Extended onboarding timelines that assume months rather than weeks before full field deployment
  • Ongoing scientific and operational recertification as the evidence base and label evolve
  • Specialized roles that don’t exist in standard specialty models, which may include patient educators, access experts, field reimbursement managers, and nurse educators embedded with ATCs
  • Deliberate hiring for scientific depth, comfort with complexity, and the interpersonal skills to navigate multi-stakeholder institutions
  • Deployment of training beyond core field roles to all team members who may interact externally, even if they are predominantly headquarters-based

 

Manufacturers that under-invest here discover the gap in the worst possible setting: a specialist asks a detailed operational question in front of colleagues, and no one on the team can answer it. That single moment costs more than the training that would have prevented it.

Build the Cross-Functional Foundation from Day One

Individual expertise, however deep, is not sufficient, and neither is simply having the functions in place. CGT commercialization requires medical, commercial, and market access teams that are actively coordinated and integrated, operating from shared strategy, consistent messaging, and clearly defined responsibilities across every stakeholder-facing activity. The reason is structural: nearly every CGT stakeholder engages with multiple functions simultaneously. An ATC medical director may interact with a medical science liaison on clinical evidence, a key account manager on institutional readiness, a field reimbursement manager on coverage, and a patient services lead on logistics, sometimes within the same week. If those functions are not aligned on strategy, priorities, and messaging, each stakeholder may view the manufacturer as fragmented and slow.

Integration matters most around timelines. Site qualification and first treatments never move as fast as anyone wants, and the ATCs that struggle most are the ones getting different accounts of where things stand from different functions. When every function tells the same story about status, next steps, and why the sequence takes as long as it does, sites stay engaged through delays no one can control. When the story changes with the messenger, delays are perceived as evidence that no one is in charge.

The foundational work here is not glamorous, but it is necessary and decisive. It includes shared account plans that all functions can see and contribute to, clear governance on who owns which stakeholder relationship, agreed-upon messaging that adapts to audience without contradicting itself across channels, and a cadence of cross-functional review that identifies issues before they reach the field. This kind of alignment is difficult to retrofit once the launch is underway. It is much easier to build it in from the start, ideally 12 to 18+ months ahead of launch, when the team is still small enough for alignment to be a conversation rather than a process.

Role clarity and coordination also depend on a shared scientific and technical foundation. Every team member who may face an external audience, not just field roles, should understand the platform and manufacturing process well enough to handle whatever comes their way, such as a specialist’s detailed mechanism-of-action question, a misconception about gene therapy safety, a broader public concern, or a nuance specific to the manufacturer’s own platform or process. When that depth is uneven across functions, the team’s weakest answer becomes the stakeholder’s impression of the whole organization.

Orchestrate the Handovers That Actually Determine Trust

The most visible failures of coordination happen at handoffs. A referring physician who was told one thing by the field medical team and something different by the patient services team will remember the discrepancy longer than either of the individual conversations. An ATC pharmacist who is passed from a key account manager to a field reimbursement manager to a patient services coordinator, each of whom asks the same intake questions, will conclude that the manufacturer is not organized, regardless of how capable everyone is. And a payer medical director who receives inconsistent evidence framing from medical and access teams will discount the entire dossier.

Orchestrating seamless handoffs is therefore a core commercial capability. In practice, this means a single shared view of each stakeholder’s needs, history, and open questions that every function can access; joint call planning across functions; warm introductions rather than cold escalations; and explicit protocols for what information gets carried forward at each transition. The goal is for each stakeholder to experience continuity across every touchpoint, even as the underlying functions rotate in and out of the lead role.

This is also where earlier investments in engagement (part 6) and patient support (part 7) either compound or unravel. Coordinated internal teams make those external programs feel coherent, while uncoordinated ones make even well-designed programs feel disjointed at the point of delivery.

The Bottom Line

CGT commercialization is a team effort executed at a higher level of technical and operational complexity than most commercial organizations have been built for. That reality demands deeper expertise in every externally facing role, tighter cross-functional alignment on strategy and messaging, and deliberate orchestration of the handoffs that determine how stakeholders experience the manufacturer. Manufacturers that invest in these foundations early are experienced as organized and credible while those that don’t are experienced as fragmented. In a modality where stakeholders are still deciding whether to trust the science at all, fragmentation can be seen as an indicator of risk, not just in the team, but also in the therapy.

Next in the series: Success Factor 9 – Commercial Foundation and Infrastructure.